Sun Pharmaceutical Industries is currently trading at Rs. 685.00, up by 9.40 points or 1.39% from its previous closing of Rs. 675.60 on the BSE.
The scrip opened at Rs. 680.00 and has touched a high and low of Rs. 688.80 and Rs. 680.00 respectively. So far 8,270 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.00 on 10-Aug-2012 and a 52 week low of Rs. 448.20 on 04-Oct-2011.
Last one week high and low of the scrip stood at Rs. 690.00 and Rs. 661.50 respectively. The current market cap of the company is Rs. 70,935.00 crore.
The promoters holding in the company stood at 63.72% while Institutions and Non-Institutions held 25.73% and 10.55% respectively.
Sun Pharmaceutical Industries has received an approval to spin-off the domestic formulation business of the company on a going concern basis comprising certain assets pertaining to the said business to its wholly owned subsidiary (WOS), Sun Resins & Polymers with effect from March 31, 2012. The board at its meeting held on August 10, 2012 has approved for the same.
However, the above will be effective pursuant to a proposed scheme of arrangement of the Companies Act, 1956 subject to obtaining of approvals from the shareholders, regulatory authorities including the High Court of Gujarat.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: